Analyse Fresenius stock

Plausibility check: confirmed
55.22 EUR is approx. 30.1% above the current price of 42.43 EUR and thus above the required +/-25% range, but is still justifiable for Fresenius because the valuation of P/E ratio 12.19 is rather moderate for a defensive healthcare group and the target is only just above the 52-week high of 52.96 EUR is.
Quantitative: Based on the given P/E ratio, the market currently implies a rather cautious earnings valuation; A price target of 55.22 EUR roughly corresponds to a moderate multiple expansion plus further earnings growth. Compared to historical assessment levels of quality health values,...